<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
 xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:owl="http://www.w3.org/2002/07/owl#"
 xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"
 xml:base="http://www.reactome.org/biopax/91/444257#">
<owl:Ontology rdf:about="">
 <owl:imports rdf:resource="http://www.biopax.org/release/biopax-level3.owl#" />
</owl:Ontology>

<bp:Provenance rdf:ID="Provenance1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Reactome</bp:name>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">http://www.reactome.org</bp:comment>
</bp:Provenance>

<bp:Evidence rdf:ID="Evidence1">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1">
 <bp:stepProcess rdf:resource="#Catalysis1" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction2">
 <bp:evidence rdf:resource="#Evidence3" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PDPK1 phosphorylates RSKs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1">
 <bp:evidence rdf:resource="#Evidence2" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RSKs autophosphorylate</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction4">
 <bp:evidence rdf:resource="#Evidence5" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERKs phosphorylate RSKs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction3">
 <bp:evidence rdf:resource="#Evidence4" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-S363,S380,T573 RS6K translocates to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence5">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway1">
 <bp:pathwayOrder rdf:resource="#PathwayStep1" />
 <bp:pathwayOrder rdf:resource="#PathwayStep4" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2" />
 <bp:pathwayOrder rdf:resource="#PathwayStep3" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction2" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction4" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction3" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RSK activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ribosomal S6 kinase (RSK) has four isoforms in humans, RPS6KA1 (RSK1), RPS6KA2 (RSK3), RPS6KA3 (RSK2) and RPS6KA6 (RSK4), and each of the isoforms have six conserved phosphorylation sites (in RPS6KA1, these are serine residues S221, S363 and S380 and threonine residues T359, T573 and T732). Phosphorylation at four of these residues appears to be critically important for the catalytic activity of RSKs: S221, S363, S380 and T573 (in RPS6KA1). Phosphorylation and activation of RSKs primarily occurs at the plasma membrane, but can occur in the cytoplasm and in the nucleus. ERKs (MAPK1 and MAPK3), activated downstream of RAS signaling, phosphorylate RSKs on threonine and serine residues T359, S363 and T573 (in RPS6KA1). Phosphorylation by ERKs enables autophosphorylation of RSKs on serine residue S380 and threonine residue T732 (in RPS6KA1). Phosphorylation of RSKs by PDPK1 (PDK1) at serine residue S221 (in RPS6KA1) is necessary for the full activation of RSKs and phosphorylation of RSK substrates (reviewed by Anjum and Blenis 2012). RSK4 differs from other RSKs because it shows high level of constitutive phosphorylation and activity in the absence of growth factors, although it is still responsive to growth factors and ERK activity (Dummler et al. 2005). RSKs, especially RSK2, are highly expressed in brain regions with high synaptic activity. RSK2 mutations are the underlying cause of Coffin-Lowry syndrome (CLS), which is characterized by cognitive impairment and skeletal anomalies (Zeniou et al. 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence3">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence4">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis1">
 <bp:controlled rdf:resource="#BiochemicalReaction1" />
</bp:Catalysis>

<bp:BioSource rdf:ID="BioSource1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Homo sapiens</bp:name>
</bp:BioSource>

<bp:Catalysis rdf:ID="Catalysis2">
 <bp:controlled rdf:resource="#BiochemicalReaction2" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis3">
 <bp:controlled rdf:resource="#BiochemicalReaction4" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep4">
 <bp:stepProcess rdf:resource="#Catalysis3" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction4" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2">
 <bp:stepProcess rdf:resource="#Catalysis2" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep3">
 <bp:stepProcess rdf:resource="#BiochemicalReaction3" />
</bp:PathwayStep>
</rdf:RDF>